For ITP patients in New York who have not achieved adequate platelet response on the starting dose of 25mg, Platify 50 — containing Eltrombopag Olamine 50mg — offers the next dose step in the titration strategy recommended by the American Society of Hematology (ASH) ITP guidelines. Understanding the safety profile and monitoring requirements of this higher dose is essential for both patients and prescribing haematologists.
Eltrombopag 50mg is typically initiated when the 25mg dose has not produced a platelet count of at least 50 x 10⁹/L after 2 weeks of treatment. The dose may be further increased to 75mg if necessary, in 2-weekly increments. New York haematologists at Columbia University Irving Medical Center, Mount Sinai, and Northwell Health regularly manage ITP patients through this titration process, monitoring platelet counts every 1-2 weeks until a stable maintenance dose is achieved.
Key safety considerations with Platify 50 include regular liver function testing every 2 weeks during dose initiation and monthly thereafter, monitoring for signs of thrombosis (blood clots), and awareness of the risk of bone marrow reticulin formation with very long-term use. These risks are manageable with appropriate monitoring and are outweighed by the significant benefit of maintained platelet counts and reduced bleeding risk in chronic ITP.
Unnati Pharmax supplies Platify 50 (Eltrombopag 50mg) to ITP patients, haematology clinics, and pharmacies in New York and across the USA. Contact medshopy.com or WhatsApp +91 82650 41513.
